noodls browser compatibility check

The security settings of your browser are blocking the execution of scripts.

To use noodls, javascript support must be enabled. Please change your browser's security settings to enable javascript.

If you have changed your browser's security settings, you can click here.

related announcements

News

Sage Therapeutics Inc.

Sage Therapeutics Board of Directors Initiates Review of Strategic[...]
City of Tampa, FL

Affordable Housing Complex Opens on S. Manhattan Avenue News General,[...]
The University of Tennessee Health[...]

Office of Academic Success Newsletter

Healthcare

Eisai Inc.

01/26/2025 | Press release | Distributed by Public on 01/26/2025 17:40

FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease

Read this content

Click here to read the original version at the source's official website. The text of this article is not available at the moment.

Sharing and Personal Tools

Please select the service you want to use:

Smartlinks | Eisai Inc. | Eisai Co. Ltd. | News | Health | Science | Research | Local News | Politics and Policy | Policy and Regulation | Company News | Top Company News | Business Announcement | Products and Services | Corporate Litigation and Regulation | Pharmaceuticals | Private Companies | Pharmaceutical Companies

Back